Gilead to buy CymaBay in $4.3B deal for liver disease drug

Foster City, CA,  February 12, 2024 (Yahoo Finance) -- Gilead Sciences announces acquisition of CymaBay Therapeutics in a $4.3 billion deal.  The proposed acquisition will grant Gilead access to an experimental treatment CymaBay's liver disease drug for primary biliary cholangitis.

Read full article here.